medigraphic.com
ISSN 1561-2988 (Print)

2020, Number 1

<< Back Next >>

Rev Cubana Farm 2020; 53 (1)

Dissolution profile of captopril by simulation of pre-surgical and post-surgical conditions of bariatric surgery in Colombia

Utria ALA, Martínez ZJ, Mercado CJ, Alviz AA

Language: Spanish
References: 15
Page: 1-17
PDF size: 531.74 Kb.


ABSTRACT

Introduction: Obese patients, after bariatric surgery, present cardiovascular comorbidities, such as hypertension, which require oral treatments with drugs for decreasing or modulating their blood pressure.
Objective: To compare the dissolution profile of commercial presentations of captopril in 50-mg tablets, simulating pre-surgical and post-surgical conditions of bariatric surgery by means an in vitro model.
Methods: A biopharmaceutical study of dissolution profile was carried out with eight generic brands of captopril, by simulating the gastrointestinal conditions of preoperative and postoperative patients who received bariatric surgery and according to the specifications established in the United States Pharmacopeia 38 for the pre-surgical medium and adapting the post-surgical medium to physiological conditions. The behavior of each drug in the different media was compared.
Results: The dissolution efficiency in both pre-surgical and post-surgical media for all brands was 86.3% and 83.5%, respectively, with the exception of the brands M and R, which presented differences between the media. The area under the curve did not show significant differences between the media (pre-surgical: 2588.2; post-surgical: 2505.7).
Conclusions: There are significant differences between the dissolution profiles of the preoperative and postoperative media in some brands of captopril traded in in Colombia. This makes it possible to infer possible therapeutic failures in post-bariatric patients with hypertension treated with the brands M and R of captopril, since these do not guarantee biopharmaceutical equivalence according to the United States Pharmacopeia 38 and due to their lower dissolution percentages found in the model under postoperative conditions.


REFERENCES

  1. Csendes JA, Lembach JH. Fisiopatología en la cirugía de la obesidad: Gastrectomía vertical subtotal y bypass gástrico. Revista chilena de cirugía. 2010;62(5):525-31. DOI: 10.4067/S0718-40262010000500019

  2. Ramírez J, Carpio D, Mezzano S, Mukdsi J, Ardiles L. Cirugía bariátrica en pacientes con glomeruloesclerosis focal y segmentaria secundaria a obesidad. Nefrología. 2009;29(3):266- 69. DOI: 10.3265/Nefrologia.2009.29.3.5085.en.full

  3. Lleras DlaFC. Encuesta Nacional de la Situación Nutricional en Colombia 2010. Bogotá: Minsalud; 2015. [acceso 15/05/2019]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/Base de datos ENSIN - Protocolo Ensin 2010.pdf%5Cn%5Cn

  4. Yupanqui H, Muñoz JM, Guerra L. Bogotá DC. Obesidad y cirugía bariátrica. Acta Médica Colombiana. 2008 [acceso 14/05/2019];33(1):15-21. Disponible en: http://www.scielo.org.co/pdf/amc/v33n1/v33n1a4.pdf

  5. Fraile-Gomez P, Dominguez-Quiben S, Sebastia-Morant J, Lucas-Alvarez C, Tabernero- Romo JM. Bariatric surgery, a new cause of acute renal failure. Nefrología. 2013;33(Dm):616-18. DOI:10.3265/Nefrologia.pre2013.Apr.11931

  6. Gubbins PO, Bertch KE. Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications. Clinical pharmacokinetics. 1991;21(6):431- 47. DOI:10.2165/00003088-199121060-00004

  7. Seaman JS, Bowers SP, Dixon P, Schindler L. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics. 2005;46(3):250-53. DOI:10.1176/appi.psy.46.3.250

  8. Padwal R, Brocks D, Sharma M. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obesity Reviews. 2010;11(1):41-50. DOI:10.1111/j.1467-789X.2009.00614.x

  9. Worland PJ, Drummer OH, Jarrott B. Gastric and intestinal absorption of captopril in acutely and chronically treated rats: Comparison with salicylic acid. Journal of Pharmaceutical Sciences. 1984;73(12):1755-58. DOI:10.1002/jps.2600731224

  10. Brocks DR, Ben-Eltriki M, Gabr RQ, Padwal RS. The effects of gastric bypass surgery on drug absorption and pharmacokinetics. Expert opinion on drug metabolism & toxicology. 2012;8(12):1505-19. DOI:10.1517/17425255.2012.722757

  11. Smith A, Henriksen B, Cohen A. Pharmacokinetic considerations in Roux-en-Y gastric bypass patients. American Journal of Health-System Pharmacy. 2011;68(23):2241-47. DOI:10.2146/ajhp100630

  12. Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. American Journal of Health-System Pharmacy. 2006;63(19):1852-57. DOI:10.2146/ajhp060033

  13. Eduardo G, Melo M, Cavallo ER. Estudio comparativo de la calidad biofarmacéutica de marcas comerciales y multifuentes de tabletas de captopril y losartán del mercado colombiano Resumen Comparative study of the biopharmaceutical quality of Introducción. Rev Colomb Cienc Quím Farm. 2014;43(2):217-33.

  14. USP, NF. United States Pharmacopeia and National Formulary (USP 38–NF 33). vol. 2 EE. UU.: USP: NF; 2016. p 2577-2578.

  15. Joaquin JS, Arroyo GA. Calificación de la equivalencia farmacéutica in vitro por la metodología HPLC de cuatro medicamentos conteniendo paracetamol, clorfenamina maleato. Rev Soc Quím Perú. 2016;82(4):415-30.




2020     |     www.medigraphic.com